> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Bayer’s Aliqopa
- URL: https://www.fdaweb.com/regulatory-review-period-for-bayers-aliqopa/
- Published: 2023-02-15T12:00:00.000Z
- Updated: 2026-09-14T18:16:10.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5153782

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Bayer’s Aliqopa (copanlisib dihydrochloride), indicated for treating adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The regulatory review period is 3,004 days, of which 2,821 days occurred during the testing phase and 183 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-02-14/pdf/2023-03070.pdf?ref=fdaweb.com).